Amgen Inc. (AMGN)
AMGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AMGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1983 |
| SEC CIK | 0000318154 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $36.8B |
| Net income | $7.7B |
| Operating income | $9.1B |
| Net margin | 21.0% |
| Operating margin | 24.7% |
| Revenue growth | +10.0% |
| Cash | $9.1B |
| Total assets | $90.6B |
| P/E (computed) | 32.4× |
| P/S (computed) | 6.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $13.2B cash; operating cash flow $3.0B a quarter. | Report 2026-09-30 |
| Shares outstanding | 540,911,490 (2026-10-29); 538,480,671 a year earlier; 535,178,027 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-02-24 |
| Auditor | Ernst & Young LLP, Los Angeles, California, United States | PCAOB Form AP 2026-03-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $29.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $10.4B | $3.9B | $4.2B | $13.2B | $54.0B | $38.9B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $10.1B | $2.4B | $4.0B | $14.0B | $57.3B | $38.1B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $8.6B | $1.8B | $2.2B | $12.0B | $57.3B | $37.2B | 10-Q 2026-05-01 |
| Q4 2025 2025-12-31 | $9.9B | $1.3B | $1.6B | $9.1B | $54.6B | $36.8B | 10-K 2026-02-13 |
| Q3 2025 2025-09-30 | $9.6B | $3.2B | $4.7B | $9.4B | $54.6B | $36.0B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $9.2B | $1.4B | $2.3B | $8.0B | $56.2B | $34.9B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $8.1B | $1.7B | $1.4B | $8.8B | $57.4B | $34.1B | 10-Q 2026-05-01 |
| Q4 2024 2024-12-31 | $9.1B | $627.0M | $4.8B | $12.0B | $60.1B | $33.4B | 10-K 2026-02-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-02-19 |
| Latest annual report | 10-K | 2026-02-13 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.1% |
| 1 month | +12.8% |
| 3 months | +11.4% |
| Year to date | +42.3% |
| 1 year | +38.6% |
| From 52-week high | -2.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GILD | Gilead Sciences Inc. | $167.58 | -0.30% | $207.9B |
| MRNA | Moderna Inc. | $215.27 | -3.63% | $87.1B |
| ARGX | argenx SE | $950.95 | -0.95% | $59.0B |
| BIIB | Biogen Inc. | $251.65 | -0.69% | $37.2B |
| RVMD | Revolution Medicines Inc. | $166.87 | -3.15% | $36.1B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier